Program-Level Neoadjuvant Chemotherapy Use and 10-Year Survival in Advanced Ovarian Cancer
This comparative effectiveness research examines the association between neoadjuvant chemotherapy adoption by US cancer programs and 10-year survival among patients with advanced ovarian cancer.
Authors
- NL Keating
- Alicia Youssef (ORCID: https://orcid.org/0000-0002-1140-7282)
- D. Jenkins
- William Manning
- Amy Bregar
- Alex E. R. Powers
- Alejandro Rauh-Hain
- Alexander Melamed
- Gretchen Davis
- Jason D. Wright
Institutions
- Tufts University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Mass General Brigham (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-09-17
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.34330
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00